Papanikolaou S, Emmanouilidou E, Adamichou C, Kalogiannaki E, Nikolopoulos D, Fredi M, Carter LM, Tani C, Kapsala N, Repa A, Malissovas N, Garantziotis P, Avgoustidis N, Nikoleri D, Banos A, Vatsellas G, Sidiropoulos P, Konstantopoulos D, Boumpas D, Vital EM, Andreoli L, Mosca M, Inês L, Nikolaou C, Bertsias G. (2026) Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment. Ann Rheum Dis. doi: 10.1016/j.ard.2026.02.003.
Beretta L, Chan CWS, Moysidou GS, Nöthling DM, Ainatzoglou A, Zoli A, Katechis S, Fanouriakis A, Bozec A, Sidiropoulos P, Bergmann C, Boumpas DT, Schett G, Bertsias G, Garantziotis P. (2026) Molecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response. J Autoimmun. 159:103525.
Kosmara D, Papanikolaou S, Stathopoulou C, Papamatheakis D, Vatsellas G, Cimmarrusti A, Banos A, Sidiropoulos P, Lavigne MD, Verginis P, Boumpas D, Spilianakis C, Konstantopoulos D, Nikolaou C, Bertsias G. (2025) The sex-biased chromatin modifier SMC1A promotes autoimmunity by shaping inflammatory pathways in patients with SLE. Nat Commun. 16:10350.
Kosmara D, Papanikolaou S, Nikolaou C, Bertsias G. (2023) Extensive Alternative Splicing Patterns in Systemic Lupus Erythematosus Highlight Sexual Differences. Cells. 12:2678.
Georgakis S, Gkirtzimanaki K, Papadaki G, Gakiopoulou H, Drakos E, Eloranta ML, Makridakis M, Kontostathi G, Zoidakis J, Baira E, Rönnblom L, Boumpas DT, Sidiropoulos P, Verginis P, Bertsias G. (2021) NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE. JCI Insight. 6:e147671.
Nikoloudaki M, Barmparis GD, Pitsigavdaki S, Katechis S, Silvagni E, Repa A, Marangoni A, Avgoustidis N, Flouri I, Saridakis I, Govoni M, Sidiropoulos P, Fanouriakis A, Bortoluzzi A, Boumpas D, Bertsias G. Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study. RMD Open. 2026; 12(1): e006424. doi: 10.1136/rmdopen-2025-006424
Garantziotis P, Nikolopoulos D, Katechis S, Temiz A, Nöthling DM, Adamichou C, Bergmann C, Sidiropoulos P, Schett G, Fanouriakis A, Boumpas DT, Bertsias G. Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage. RMD Open. 2025; 11(3): e006009. doi: 10.1136/rmdopen-2025-006009.
Garantziotis P, Beretta L, Lindblom J, Moysidou GS, Nikolopoulos D, Grieshaber-Bouyer R, Hagen M, Bergmann C, Wirsching A, Bozec A; PRECISESADS Clinical Consortium; Schneider M, Barturen G, Bertsias G, Boumpas DT, Alarcón-Riquelme ME, Mackensen A, Schett G, Parodis I. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann Rheum Dis. 2026; 85(1): 153-163. doi: 10.1016/j.ard.2025.06.2132.
Moysidou GS, Garantziotis P, Sentis G, Nikoleri D, Malissovas N, Nikoloudaki M, Stergioti EM, Polia S, Paschalidis N, Filia A, Grigoriou M, Nikolopoulos D, Kapsala N, Katechis S, Fanouriakis A, Bertsias G, Boumpas DT. Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann Rheum Dis. 2025; 84(2): 262-273. doi: 10.1136/ard-2024-226051
Katechis S, Pitsigavdaki S, Nikoloudaki M, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Govoni M, Sidiropoulos P, Boumpas DT, Fanouriakis A, Bertsias G, Bortoluzzi A. Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study. RMD Open. 2025; 11(1): e005118. doi: 10.1136/rmdopen-2024-005118
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann Rheum Dis. 2024; 83(4): 464-474. doi: 10.1136/ard-2023-224919.
Emmanouilidou E, Kosmara D, Papadaki E, Mastorodemos V, Constantoulakis P, Repa A, Christopoulou G, Kalpadakis C, Avgoustidis N, Thomas K, Boumpas D, Sidiropoulos P, Bertsias G. (2023) Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors? J Clin Med. 12: 6945.
Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, Ustek D, Satorius C, Ueda A, Takeno M, Kim Y, Wood GM, Ombrello MJ, Meguro A, Gul A, Remmers EF, Kastner DL. (2013) Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 45:202-7.
Papanikolaou S, Bertsias GK, Nikolaou C. Extensive Changes in Transcription Dynamics Reflected on Alternative Splicing Events in Systemic Lupus Erythematosus Patients. Genes (Basel). 2021; 12(8): 1260. doi: 10.3390/genes12081260.
Gkirtzimanaki K, Kabrani E, Nikoleri D, Polyzos A, Blanas A, Sidiropoulos P, Makrigiannakis A, Bertsias G, Boumpas DT, Verginis P (2018). IFNα Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. Cell Rep. 25(4): 921-933.e5.
Ntasis VF, Panousis NI, Tektonidou MG, Dermitzakis ET, Boumpas DT, Bertsias GK, Nikolaou C. Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. Sci Rep. 2020; 10(1): 16648. doi: 10.1038/s41598-020-73654-4.
Stathopoulou C, Nikoleri D, Bertsias G (2019). Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. Immunotherapy. 11(9): 813-829.
Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M, Romano-Palumbo L, Bielser D, Howald C, Pamfil C, Fanouriakis A, Kosmara D, Repa A, Sidiropoulos P, Dermitzakis ET, Boumpas DT. (2019) Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis. 78: 1079-1089.
Krasoudaki E, Banos A, Stagakis E, Loupasakis K, Drakos E, Sinatkas V, Zampoulaki A, Papagianni A, Iliopoulos D, Boumpas DT, Bertsias GK. (2016) Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. Nephrol Dial Transplant. 31:1676-86.
